Bristol-Myers Squibb (NY:BMY)

59.02 -2.13 (-3.48%)

Delayed Quote Updated: 12:26 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

From BioMedWire

Via GlobeNewswire

Bristol-Myers Squibb (NYSE:BMY) Passes the Dividend Screen, but Payout Sustainability Is the Key Question ↗

September 10, 2026

Via Chartmill

Bristol-Myers Squibb (NYSE:BMY) Flashes Strong Technical Breakout Setup ↗

September 05, 2026

Via Chartmill

Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...

September 08, 2026

From Bristol Myers Squibb

Via Business Wire

BioNTech vs. Moderna: Which Is the Better Cancer Vaccine Stock to Buy Now? ↗

September 03, 2026

Both have attracted considerable attention from Wall Street recently.

Via The Motley Fool

Is BioNTech Stock a No-Brainer Buy on the Dip? ↗

September 02, 2026

The company is coming back into the spotlight thanks to recent developments.

Via The Motley Fool

2 Absurdly Cheap Dividend Stocks to Buy With $1,000 Right Now ↗

September 02, 2026

If you're looking to invest $1,000 in a dividend stock, look to the pharmaceutical sector.

Via The Motley Fool

Branded Pharmaceuticals Stocks Q2 Teardown: Bristol-Myers Squibb (NYSE:BMY) Vs The Rest

August 31, 2026

The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Reasons to Sell BMY and 1 Stock to Buy Instead

August 31, 2026

Even though Bristol-Myers Squibb (currently trading at $66.44 per share) has gained 6.6% over the last six months, it has lagged the S&P 500’s 12.3% return d...

Via StockStory

Topics Stocks

Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026

August 29, 2026

From Bristol Myers Squibb

Via Business Wire

Opinion: Bristol Myers Squibb Is a Buy -- but the Real Reason Why Might Surprise Investors ↗

August 29, 2026

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

Via The Motley Fool

Topics Intellectual Property

1 S&P 500 Stock with Promising Prospects and 2 Facing Challenges

August 28, 2026

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

Via StockStory

Topics Stocks

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:BNTX),(NYSE:AZN),(NASDAQ:MRNA),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

A Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest Opportunity

August 26, 2026

A New Generation of Personalized Cancer Treatments Could Open a Multibillion-Dollar Market for Precision Oncology

From MarketNewsUpdates.com

Via GlobeNewswire

3 Dividend Stocks to Hold for the Next 10 Years ↗

August 25, 2026

These healthcare leaders are unlikely to suspend their dividend programs.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset? ↗

August 21, 2026

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

Via The Motley Fool

Topics ETFs

Pharmaceuticals Stocks Q2 Highlights: Ocular Therapeutix (NASDAQ:OCUL)

August 20, 2026

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)

August 19, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...

Via StockStory

Topics Artificial Intelligence Intellectual Property

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

August 18, 2026

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Via The Motley Fool

1 Momentum Stock on Our Buy List and 2 We Turn Down

August 17, 2026

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Via StockStory

Are Mega-Mergers Back? ↗

August 15, 2026

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

Via The Motley Fool

Topics Intellectual Property

AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

August 14, 2026

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

Via The Motley Fool

Topics Intellectual Property

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen? ↗

August 13, 2026

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

Via The Motley Fool

U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS™, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse

August 13, 2026

From Bristol Myers Squibb

Via Business Wire

Pfizer Just Raised Its 2026 Guidance -- but the Boost Leans Heavily on a Drug Running Out the Patent Clock ↗

August 11, 2026

This problem has a solution, and Pfizer is implementing it.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas

August 10, 2026

From Bristol Myers Squibb

Via Business Wire

1 Profitable Stock with Impressive Fundamentals and 2 We Avoid

August 10, 2026

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Via StockStory

Bristol-Myers Squibb’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 06, 2026

Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Managemen...

Via StockStory

Topics Earnings

Bristol-Myers Squibb (BMY) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Via The Motley Fool

Topics Earnings

Which S&P500 stocks are moving before the opening bell on Monday? ↗

August 03, 2026

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

93 94 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.